Omega 3 Fatty Acid Therapy for Prevention of Vaso-occlusive Crisis and Manifestations in Omani Patients With Sickle Cell Disease

Study point of contact

Anil Pathare, MD,PhD
[email protected];[email protected]
Salam Alkindi, MD, FRCPI
[email protected];[email protected]


1 Oman site


13 to 70 Years


Phase 3

Study type





Dietary Supplement



About the study

140 SCD patients [70 on Hydroxyurea] will receive Omega-3 capsules whereas another 140 SCD
patients [70 on Hydroxyurea] will receive placebo and will be recruited from the Sultan
Qaboos University Hospital [SQUH] haematology specialty clinics. Patients will be randomized
in a 1:1 ratio to receive placebo or Omega-3 for 52 weeks. The aim is to investigate the
therapeutic potential of omega-3 fatty acids in the prevention of vaso-occlusive crisis in
Omani patients with sickle cell disease[SCD].

participation requirements

– Moderate to severe Sickle cell disease patients.

– Patients already receiving Hydroxyurea[HU] are eligible for the study.

– Patients able and willing to comply with the procedures in the study protocol.

participation restrictions

– Acute episodes (infection, vaso-occlusive crises (VOC), acute chest syndrome (ACS),
stroke, priapism, splenic sequestration) in the past one month before enrolment.

– Previous stroke, and other co-morbid diseases like Essential Hypertension,
Cardiomyopathy and Heart failure, Diabetes, Chronic Renal Failure.

– Patients with a history of adverse reaction to omega-3 fatty acid supplementation.

– Blood transfusion in the previous 3 months.


  • Muscat, Oman, Department of Haematology, Sultan Qaboos University, 123